Review

cdb tnl (Native Antigen Inc)

Name: cdb tnl
Brand: Native Antigen Inc
Rating: 90 (5 reviews)

Native Antigen Inc is a verified supplier

Native Antigen Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Native Antigen Inc cdb tnl
Cdb Tnl, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 90/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdb tnl/product/Native Antigen Inc
Average 90 stars, based on 5 article reviews

cdb tnl - by Bioz Stars, 2026-02

90/100 stars

Images

Image Search Results

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Comparison of Serum and Stool Analyte Measurements in Study Cohorts

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Comparison, Enzyme-linked Immunosorbent Assay

Dot plots showing the distribution of GCSF concentrations (pg/mL) in 6 cohorts: patients with symptomatic CDI (CDI-NAAT, defined by positive stool NAAT result and new-onset diarrhea), asymptomatic carriers (Carrier-NAAT, defined by positive stool NAAT result and absence of diarrhea), NAAT-negative patients with diarrhea (Diarrhea, NAAT-neg) and without diarrhea (No diarrhea, NAAT-neg), and symptomatic (CDI-Tox20) versus asymptomatic (Carrier-Tox20) cohorts (subsets of CDI-NAAT and Carrier-NAAT, defined by positive stool NAAT result and stool toxin A+B ≥20 pg/mL by Simoa). The bottom and top edges of the boxes for each cohort indicate the IQR, the horizontal line bisecting the box indicates the median value, and the whiskers represent values up to 1.5 IQR. The inset table indicates P values for comparison of median values for paired cohorts as indicated. Abbreviations: CDI, Clostridioides difficile infection; GCSF, granulocyte colony-stimulating factor; IQR, interquartile range; n/a, not applicable; NAAT, nucleic acid amplification test; neg, negative; Simoa, Single Molecule Array; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of GCSF concentrations (pg/mL) in 6 cohorts: patients with symptomatic CDI (CDI-NAAT, defined by positive stool NAAT result and new-onset diarrhea), asymptomatic carriers (Carrier-NAAT, defined by positive stool NAAT result and absence of diarrhea), NAAT-negative patients with diarrhea (Diarrhea, NAAT-neg) and without diarrhea (No diarrhea, NAAT-neg), and symptomatic (CDI-Tox20) versus asymptomatic (Carrier-Tox20) cohorts (subsets of CDI-NAAT and Carrier-NAAT, defined by positive stool NAAT result and stool toxin A+B ≥20 pg/mL by Simoa). The bottom and top edges of the boxes for each cohort indicate the IQR, the horizontal line bisecting the box indicates the median value, and the whiskers represent values up to 1.5 IQR. The inset table indicates P values for comparison of median values for paired cohorts as indicated. Abbreviations: CDI, Clostridioides difficile infection; GCSF, granulocyte colony-stimulating factor; IQR, interquartile range; n/a, not applicable; NAAT, nucleic acid amplification test; neg, negative; Simoa, Single Molecule Array; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Comparison, Infection, Amplification

Dot plots showing the distribution of IL-6 concentrations (pg/mL) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IL, interleukin; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of IL-6 concentrations (pg/mL) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IL, interleukin; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Infection, Amplification

Dot plots showing the distribution of TNF-α concentrations (pg/mL) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; NAAT, nucleic acid amplification test; neg, negative; TNF-ɑ, tumor necrosis factor ɑ; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of TNF-α concentrations (pg/mL) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; NAAT, nucleic acid amplification test; neg, negative; TNF-ɑ, tumor necrosis factor ɑ; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Infection, Amplification

Dot plots showing the distribution of serum IgG anti–toxin A concentrations (ELISA units) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; NAAT, nucleic acid amplification test; neg, negative; toxA, toxin A; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of serum IgG anti–toxin A concentrations (ELISA units) in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; NAAT, nucleic acid amplification test; neg, negative; toxA, toxin A; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Enzyme-linked Immunosorbent Assay, Infection, Amplification

Dot plots showing the distribution of the relative fluorescent values for stool IgA anti–toxin B detection, as measured on a VIDAS platform, in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IgA, immunoglobulin A; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of the relative fluorescent values for stool IgA anti–toxin B detection, as measured on a VIDAS platform, in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IgA, immunoglobulin A; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Infection, Amplification

Dot plots showing the distribution of the relative fluorescent values for stool IgG anti–toxin B detection, as measured on a VIDAS platform, in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IgG, immunoglobulin G; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Dot plots showing the distribution of the relative fluorescent values for stool IgG anti–toxin B detection, as measured on a VIDAS platform, in the same 6 cohorts defined in Figure 1. Abbreviations: CDI, Clostridioides difficile infection; IgG, immunoglobulin G; NAAT, nucleic acid amplification test; neg, negative; Tox20, CDI-NAAT or Carrier-NAAT cohorts who had stool toxin A+B concentrations of ≥20 pg/mL.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Infection, Amplification

Receiver operating curve indicating the accuracy of GCSF concentrations for discriminating between patients with symptomatic CDI (CDI-NAAT, defined by positive stool NAAT result and new-onset diarrhea) and asymptomatic carriers (Carrier-NAAT, defined by positive stool NAAT result and absence of diarrhea). The AUC is 0.842. Abbreviations: AUC, area under the curve; CDI, Clostridioides difficile infection; GCSF, granulocyte colony-stimulating factor; NAAT, nucleic acid amplification test.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non– C. difficile Diarrhea

doi: 10.1093/cid/ciz330

Figure Lengend Snippet: Receiver operating curve indicating the accuracy of GCSF concentrations for discriminating between patients with symptomatic CDI (CDI-NAAT, defined by positive stool NAAT result and new-onset diarrhea) and asymptomatic carriers (Carrier-NAAT, defined by positive stool NAAT result and absence of diarrhea). The AUC is 0.842. Abbreviations: AUC, area under the curve; CDI, Clostridioides difficile infection; GCSF, granulocyte colony-stimulating factor; NAAT, nucleic acid amplification test.

Article Snippet: Clostridioides difficile toxin B (Native Antigen Company) coated on a Solid Phase Receptacle was used to capture anti–toxin B Ig present in the sample.

Techniques: Infection, Amplification

C. difficile toxin concentrations in samples in various result categories. The Singulex Clarity C. diff toxins A/B assay concentrations (combined TcdA and TcdB concentrations) are shown for stool samples with different PCR (Xpert C. difficile/Epi), EIA (C. Diff Quik Chek Complete), and CCNA results. The dashed line shows the preliminary cutoff value for the Singulex Clarity C. diff toxins A/B assay.

Journal: Journal of Clinical Microbiology

Article Title: Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology

doi: 10.1128/JCM.00908-18

Figure Lengend Snippet: C. difficile toxin concentrations in samples in various result categories. The Singulex Clarity C. diff toxins A/B assay concentrations (combined TcdA and TcdB concentrations) are shown for stool samples with different PCR (Xpert C. difficile/Epi), EIA (C. Diff Quik Chek Complete), and CCNA results. The dashed line shows the preliminary cutoff value for the Singulex Clarity C. diff toxins A/B assay.

Article Snippet: TcdA (CDA-TNL-100; Native Antigen Company) and TcdB (CDB-TNL-100; Native Antigen Company) were spiked at 12 different concentrations, at a TcdA-TcdB concentration ratio of 1:1, into pooled C. difficile -negative stool (range, 0 to 50,000 pg/ml) and antigen-free sample diluent (TBS-EDTA with 3% BSA) (range, 0 to 10,000 pg/ml).

Techniques: Diff-Quik

Review

Structured Review

Images

Similar Products

Image Search Results